查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1924662

Enzalutamide軟膠囊市場按劑量、購買類型、適應症、通路和最終用戶分類 - 全球預測 2026-2032

Enzalutamide Soft Capsules Market by Dosage Strength, Purchase Type, Indication, Distribution Channel, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 185 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，Enzalutamide軟膠囊市場價值將達到 27.2 億美元，到 2026 年將成長至 29.8 億美元，到 2032 年將達到 55.7 億美元，複合年成長率為 10.78%。

關鍵市場統計數據
基準年 2025 27.2億美元
預計年份：2026年 29.8億美元
預測年份 2032 55.7億美元
複合年成長率 (%) 10.78%

在不斷發展的臨床實踐、製劑方面的考慮、監管壓力和相關人員的決策需求框架內，策略性地引Enzalutamide軟膠囊

Enzalutamide軟膠囊在現代攝護腺癌治療中佔據著重要的治療地位，口服雄性激素受體抑制劑已徹底改變了臨床路徑和患者管理。該化合物的臨床特性以靶向雄性激素受體拮抗作用為特徵，拓展了去勢抗性和激素敏感性疾病的治療選擇，因此，製劑、劑量和給藥方案的選擇成為臨床實踐和商業策略的核心挑戰。隨著新適應症和聯合治療的出現，相關人員必須權衡不斷更新的臨床證據與耐受性、依從性和給藥物流等實際挑戰。

臨床突破、製劑創新和不斷發展的分銷模式正在共同重塑Enzalutamide軟膠囊生態系統。

在臨床證據、以患者為中心的照護模式以及不斷變化的監管要求的推動下，Enzalutamide軟膠囊治療領域正經歷著變革性的轉變。新的臨床試驗數據和真實世界研究不斷完善該藥物在去勢抗性和荷爾蒙敏感性疾病中的作用，促使治療順序和合併用藥策略進行調整。這些進展正在加速從單一療法模式轉向更全面的腫瘤治療路徑的轉變，在這種路徑中，多學科協作和個人化給藥策略的重要性日益凸顯。

評估2025年美國關稅趨勢對Enzalutamide軟膠囊採購、物流韌性與採購策略的影響

2025年美國關稅政策的累積影響為Enzalutamide軟膠囊供應鏈中的製造商、經銷商和採購團隊帶來了新的考量。關稅調整加劇了對原料採購和跨境供應結構的敏感性，促使企業重新評估其供應商組合、合約條款和庫存策略。為此，企業正在實現原料藥（API）和輔料供應商的地理多元化，以維持生產的連續性，同時降低雙邊貿易波動帶來的風險。

深度細分分析揭示了適應症、劑量、通路、最終用戶和購買方式如何相互關聯，從而影響Enzalutamide軟膠囊的採用和獲取。

對Enzalutamide軟膠囊的細分市場趨勢進行分析，發現其在適應症、劑量、通路、終端用戶和購買方式等方面呈現出微妙的模式。依適應症分類，該產品可用於治療轉移性去勢抗性前列腺癌、轉移性激素敏感性前列腺癌和非轉移性去勢抗性前列腺癌，每種適應症可進一步細分為一線、二線和三線治療。這些分層差異凸顯了針對不同適應症制定臨床訊息、收集證據以及與支付方合作的必要性，以滿足不同治療階段患者對療效和安全性的不同預期。

美洲、歐洲、中東和非洲以及亞太地區的區域趨勢和營運實際情況將決定市場准入途徑和商業化優先事項。

Enzalutamide軟膠囊的臨床應用、進入途徑和商業性發展深受區域因素影響，美洲、歐洲、中東和非洲以及亞太地區的營運和政策因素各不相同，導致最終結果差異顯著。在美洲，醫療保健系統融合了公立和私人支付方的動態，這影響著藥品目錄的談判、與專科藥房的合作以及病患援助計畫的實施。在此背景下，通常需要提供詳細的衛生經濟學數據，並與大規模機構採購者進行有針對性的溝通，以確保優先獲得藥品並簡化醫院採購流程。

主要企業如何整合臨床證據、配方策略、生產彈性以及患者支持舉措，以確保競爭優勢

Enzalutamide軟膠囊市場的競爭格局取決於臨床證據、製劑差異化、供應鏈韌性和市場推廣策略執行能力之間的平衡。主要企業正優先考慮整合生命週期管理、真實世界證據產生和病患支持計畫的策略，以保護和延長其腫瘤產品組合的相關性。策略合作、許可和生產規模優勢正成為確保供應連續性和與機構買家談判的關鍵因素。

為經營團隊提供實際有效的建議，幫助他們協調證據產生、配方策略、供應韌性和通路參與，以確保永續取得。

產業領導者應採取一系列有針對性、可操作的措施，將洞察轉化為競爭優勢，並保障患者在各種醫療環境中獲得治療的機會。首先，應優先進行針對特異性適應症的證據產生和真實世界資料收集，以明確轉移性和非轉移性疾病狀態下的治療順序、耐受性特徵和長期療效。這些證據對於與臨床醫生、付款者和監管機構的溝通至關重要，並有助於在不同治療方案中實現差異化定位。

調查方法的嚴謹性和相關人員檢驗的研究設計，結合了初步訪談、二手證據綜合和情境分析，以得出可操作的見解。

本執行摘要中總結的研究結果以嚴謹的調查方法為支撐，該方法結合了與關鍵相關人員的面對面訪談、二手文獻綜述和定性綜合分析。主要研究包括對臨床醫生、採購負責人、藥屋主任和行業高管進行結構化訪談，以收集關於臨床應用、分銷管道趨勢和供應鏈限制因素的第一手觀點。這些訪談旨在獲取營運方面的見解，並檢驗二手資訊中觀察到的趨勢。

摘要重點闡述了臨床、營運和商業部門之間的協作：保障產品可及性並維持產品相關性

總之，Enzalutamide軟膠囊的市場環境受到臨床進展、製劑和包裝考量、不斷變化的經銷模式以及地緣政治貿易趨勢等因素的共同影響，這些因素對藥物可及性和商業策略均有全面影響。相關人員必須將轉移性和非轉移性適應症的新證據與實際考量相結合，例如劑量強度偏好、經銷管道趨勢和區域法規結構。能否持續保障病患用藥取決於企業能否將臨床證據的產生與穩健的供應鏈運作以及有針對性的經銷管道合作結合。

目錄

第1章：序言

第2章調查方法

  • 研究設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查前提
  • 調查限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 市場進入策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會地圖
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章Enzalutamide軟膠囊市場：依劑量分類

  • 120 mg
  • 40mg
  • 80 mg

第9章Enzalutamide軟膠囊市場：依購買類型分類

  • 新處方箋
  • 重複處方

第10章Enzalutamide軟膠囊市場依適應症分類

  • 轉移性去勢去勢抗性前列腺癌
  • 轉移性荷爾蒙敏感性前列腺癌
  • 非轉移性去勢抗性前列腺癌

第11章Enzalutamide軟膠囊市場（依分銷管道分類）

  • 離線
  • 線上

第12章Enzalutamide軟膠囊市場（依最終用戶分類）

  • 診所
  • 醫院
    • 私立醫院
    • 公立醫院
  • 專業醫療中心

第13章Enzalutamide軟膠囊市場（按地區分類）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章Enzalutamide軟膠囊市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章Enzalutamide軟膠囊市場（按國家分類）

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章：美國Enzalutamide軟膠囊市場

第17章：中國Enzalutamide軟膠囊市場

第18章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Abbott Healthcare Private Limited
  • Adley Formulations Private Limited
  • Alizyme Healthcare Limited
  • Aprazer Healthcare Private Limited
  • Astellas Pharma Inc.
  • BDR Pharmaceuticals International Private Limited
  • Cipla Limited
  • Dr. Reddy's Laboratories Limited
  • Glenmark Pharmaceuticals Limited
  • Halsted Pharma Private Limited
  • Hetero Healthcare Limited
  • Intas Pharmaceuticals Limited
  • KK Pharma Solutions Private Limited
  • Medisus Pharma Private Limited
  • Pfizer Inc.
  • RPG Life Sciences Limited
  • Rutika Lifescience Private Limited
  • Samarth Life Sciences Private Limited
  • Sun Pharmaceutical Industries Limited
  • Zydus Lifesciences Limited
Product Code: MRR-7A380DA7C40B

The Enzalutamide Soft Capsules Market was valued at USD 2.72 billion in 2025 and is projected to grow to USD 2.98 billion in 2026, with a CAGR of 10.78%, reaching USD 5.57 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 2.72 billion
Estimated Year [2026] USD 2.98 billion
Forecast Year [2032] USD 5.57 billion
CAGR (%) 10.78%

A strategic introduction framing enzalutamide soft capsules within clinical practice evolution, formulation considerations, regulatory forces, and stakeholder decision imperatives

Enzalutamide soft capsules occupy a critical therapeutic niche within contemporary prostate cancer care, where oral androgen receptor inhibitors have reshaped clinical pathways and patient management. The compound's clinical profile, characterized by targeted androgen receptor antagonism, has expanded therapeutic options across castration-resistant and hormone-sensitive disease states, making formulation, dosage, and delivery considerations central to both clinical practice and commercial strategy. As new indications and combination regimens emerge, stakeholders must reconcile evolving clinical evidence with practical issues such as tolerability, adherence, and administration logistics.

Beyond clinical efficacy, the product format of soft capsules introduces specific supply chain and patient experience dynamics. Soft capsules can influence bioavailability, ease of swallowing, and packaging preferences, which in turn affect physician prescribing behavior and patient acceptance. Regulatory oversight and post-approval safety monitoring continue to shape label updates and risk management strategies. Consequently, manufacturers, payers, providers, and distributors require a clear, consolidated view of how clinical developments, formulation attributes, and regulatory signals converge to influence access and utilization.

This introduction frames the subsequent analysis by outlining the intersecting domains of clinical practice, product formulation, distribution channels, and end-user behavior. It establishes context for deeper sections that examine transformative shifts, tariff impacts, segmentation nuances, regional differentiators, competitive positioning, and actionable recommendations to guide strategic planning and execution.

How clinical breakthroughs, formulation innovation, and distribution model evolution are converging to redefine the enzalutamide soft capsule ecosystem

The therapeutic landscape for enzalutamide soft capsules is undergoing transformative shifts driven by clinical evidence, patient-centric care models, and evolving regulatory expectations. Novel trial data and real-world studies continue to refine the drug's role across castration-resistant and hormone-sensitive disease states, prompting adjustments in treatment sequencing and combination strategies. These developments are catalyzing a shift from single-agent paradigms to more integrated oncology care pathways where multidisciplinary coordination and individualized dosing strategies are increasingly important.

Concurrently, manufacturing and formulation innovation are influencing product differentiation. Advances in soft capsule technology aimed at improving solubility, stability, and patient adherence are providing manufacturers with levers to enhance competitive positioning. Moreover, payers and procurement bodies are imposing greater emphasis on evidentiary value, therapeutic outcomes, and cost-effectiveness, which is prompting both clinical and commercial teams to articulate clearer value propositions and real-world evidence plans.

Distribution and access models are also evolving. The rise of online pharmacies, expansion of specialty center networks, and strengthening of hospital-based oncology services are reshaping how enzalutamide reaches patients. These channel dynamics intersect with regulatory reforms and pricing dialogues, compelling stakeholders to adopt more agile commercialization strategies that align clinical benefit with operational efficiency. As a result, industry players must navigate a multipronged change environment that blends clinical innovation, product engineering, and market access sophistication.

Assessing how United States tariff developments in 2025 are reshaping sourcing, logistics resilience, and procurement strategies for enzalutamide soft capsules

The cumulative effects of United States tariff policy developments in 2025 have introduced fresh considerations for manufacturers, distributors, and procurement teams operating within the enzalutamide soft capsule supply chain. Tariff adjustments have heightened sensitivity to component sourcing and cross-border supply arrangements, encouraging firms to re-evaluate supplier portfolios, contractual terms, and inventory strategies. In response, companies are pursuing greater geographic diversification of API and excipient suppliers to reduce exposure to bilateral trade shifts while preserving manufacturing continuity.

These tariff-related pressures have ripple effects across logistics and cost-to-serve calculations, prompting a reassessment of packaging origins, transportation routing, and customs compliance processes. Firms are increasingly integrating tariff scenario planning into commercial operations, using contractual flexibility and longer-term supplier cadence agreements to insulate product availability from short-term trade volatility. Parallel to operational adjustments, procurement and pricing teams are engaging more proactively with payers and institutional buyers to explain cost dynamics while seeking outcome-based or volume-guaranteed arrangements that stabilize demand and revenue flows.

Regulatory and compliance teams are also adapting by enhancing documentation, classification accuracy, and traceability across the manufacturing footprint to expedite cross-border movement and reduce clearance delays. Collectively, these actions reflect a strategic shift toward resilient supply chain design where tariff impacts are managed through diversified sourcing, enhanced compliance, and closer collaboration with downstream stakeholders to secure uninterrupted patient access.

Deep segmentation intelligence revealing how indication, dosage, distribution, end user, and purchase type interrelate to shape enzalutamide soft capsule adoption and access

Segment-level dynamics for enzalutamide soft capsules reveal nuanced patterns when examined across indication, dosage strength, distribution channel, end user, and purchase type. When considered by indication, the product's utilization spans metastatic castration-resistant prostate cancer, metastatic hormone-sensitive prostate cancer, and non-metastatic castration-resistant prostate cancer, with each indication further differentiated by first-line, second-line, and third-line therapeutic positioning. This gradation underscores the need for indication-specific clinical messaging, evidence generation, and payer engagement to address distinct efficacy and safety expectations along the treatment continuum.

In terms of dosage strength, the product architecture includes 120 mg, 80 mg, and 40 mg presentations, each available in blister pack and bottle configurations. Formulation and packaging choices influence compliance, storage, and dispensing practices, which in turn affect formulary positioning and pharmacy stocking decisions. Distribution channels exhibit their own complexity: hospital pharmacies, online pharmacies, and retail pharmacies serve distinct patient cohorts and procurement mechanisms, with hospital channels differentiated between private and public facilities, online platforms segmented into direct-to-consumer and third-party aggregation services, and retail channels divided between chain and independent operators.

End users range from clinics, hospitals, and specialty centers, with clinics further categorized into general and specialty clinics, hospitals delineated between private and public entities, and specialty centers encompassing cancer research institutes and oncology-focused centers. Finally, purchase type distinguishes new prescriptions from refills, and refills may be either complete or partial, creating implications for adherence programs, patient support services, and refill management workflows. Taken together, these segmentation strata demand integrated commercial tactics that synchronize clinical evidence, packaging strategy, channel engagement, and patient support across the product lifecycle.

Regional dynamics and operational realities across the Americas, Europe Middle East and Africa, and Asia-Pacific that determine access pathways and commercialization priorities

Regional forces exert strong influence on clinical adoption, access pathways, and commercial execution for enzalutamide soft capsules, with distinct operational and policy drivers shaping outcomes in the Americas, Europe Middle East and Africa, and Asia-Pacific. Across the Americas, healthcare systems present a mix of private and public payer dynamics that affect formulary negotiation, specialty pharmacy integration, and patient assistance program deployment. This environment often requires robust health economics dossiers and targeted engagement with large institutional buyers to secure preferred access and streamline hospital procurement.

In Europe, the Middle East and Africa, regulatory heterogeneity and reimbursement frameworks create differentiated pathways to patient access. National and supra-national assessment bodies prioritize comparative clinical benefit and cost-effectiveness evidence, which necessitates coordinated regulatory submissions and localized value narratives. Additionally, distribution must account for variable cold chain and logistics infrastructure across extensive geographic footprints, encouraging partnerships with regional distributors and specialty logistics providers.

The Asia-Pacific region presents a mosaic of rapid uptake in urban centers, evolving domestic manufacturing ecosystems, and diverse payer constructs. Policymakers and payers in several countries are increasingly focused on domestic production incentives and price regulation, prompting manufacturers to consider local manufacturing arrangements, tiered pricing strategies, and tailored patient support mechanisms. Across all regions, harmonizing clinical evidence with operational capabilities and regulatory expectations is essential to ensure consistent access and sustainable commercialization.

How leading companies are aligning clinical evidence, formulation strategy, manufacturing resilience, and patient support initiatives to secure competitive advantage

Competitive positioning within the enzalutamide soft capsule landscape reflects a balance between clinical evidence, formulation differentiation, supply chain robustness, and go-to-market execution. Leading companies are prioritizing integrated strategies that combine lifecycle management, real-world evidence generation, and patient support programs to protect and extend the relevance of their oncology portfolios. Strategic partnerships, licensing arrangements, and manufacturing scale advantages have emerged as decisive factors in securing supply continuity and negotiating with institutional purchasers.

Companies are also investing in complementary capabilities, such as pharmacovigilance infrastructures and medical affairs engagement, to maintain regulatory compliance and strengthen clinician confidence. Investments in digital patient support platforms and adherence tools are being used to enhance persistence and outcomes, thereby reinforcing payer value propositions. On the manufacturing side, firms with geographically diversified production footprints and validated secondary suppliers are better positioned to mitigate trade disruptions and tariff-related cost pressures.

Overall, corporate strategies are increasingly multidimensional, blending clinical development, commercialization agility, and operational resilience. This integrated approach enables companies to respond to shifting clinical guidelines, adapt to local reimbursement requirements, and sustain market access through tactical collaboration with health systems, specialty pharmacies, and provider networks.

Practical, high-impact recommendations for executives to align evidence generation, formulation strategy, supply resilience, and channel engagement for sustained access

Industry leaders should adopt a set of targeted, actionable measures to translate insight into competitive advantage and to safeguard patient access across diverse healthcare settings. First, prioritize indication-specific evidence generation and real-world data collection that clarifies treatment sequencing, tolerability profiles, and long-term outcomes across metastatic and non-metastatic disease states. This evidence will be instrumental for dialogues with clinicians, payers, and regulatory bodies and will support differentiated positioning across therapy lines.

Second, optimize formulation and packaging strategies to support adherence and operational efficiency. Tailored blister and bottle presentations across 120 mg, 80 mg, and 40 mg strengths should be aligned with channel preferences and dispensing protocols in hospitals, retail pharmacies, and online platforms. Third, strengthen supply chain resilience by diversifying API and excipient sourcing, enhancing supplier qualification processes, and embedding tariff scenario planning into procurement strategies to minimize disruption risk. Fourth, refine channel engagement by developing distinct value propositions for hospital pharmacies, online platforms, and retail networks, and by aligning contractual models with institutional purchasing cycles.

Fifth, expand patient support services and refill management programs that address complete and partial refill behaviors to reduce treatment interruptions and improve outcomes. Finally, cultivate collaborative relationships with key regional stakeholders to navigate reimbursement pathways and regulatory nuances, enabling locally adaptive strategies that preserve access and sustain long-term product relevance.

Methodological rigor and stakeholder-validated research design combining primary interviews, secondary evidence synthesis, and scenario analysis for actionable intelligence

The findings synthesized in this executive summary are underpinned by a robust research methodology that combines primary stakeholder engagement, secondary literature review, and qualitative synthesis. Primary research included structured interviews with clinicians, procurement specialists, pharmacy managers, and industry executives to capture frontline perspectives on clinical utilization, channel dynamics, and supply chain constraints. These interviews were designed to elicit operational insights and to validate trends observed in secondary sources.

Secondary research encompassed regulatory documents, clinical trial reports, pharmacovigilance updates, and industry publications to construct a comprehensive view of clinical evidence, formulation attributes, and distribution practices. Data triangulation techniques were applied to reconcile disparate inputs and ensure consistency across clinical, commercial, and operational findings. Where appropriate, scenario analysis and sensitivity assessments informed strategic recommendations related to tariff impacts and supply continuity.

Throughout the research process, emphasis was placed on transparency of assumptions, traceability of sources, and stakeholder validation. The methodology prioritized relevance to decision-makers by focusing on actionable intelligence rather than descriptive summaries, and by framing insights within the operational realities faced by manufacturers, payers, and providers.

Concluding synthesis emphasizing coordination across clinical, operational, and commercial functions to protect access and sustain product relevance

In summary, the enzalutamide soft capsule landscape is defined by intersecting clinical evolution, formulation and packaging considerations, shifting distribution paradigms, and geopolitical trade dynamics that collectively influence access and commercial strategy. Stakeholders must reconcile emerging evidence across metastatic and non-metastatic indications with pragmatic considerations such as dosage strength preferences, channel behaviors, and regional regulatory frameworks. Achieving sustained patient access will depend on the ability of companies to integrate clinical evidence generation with resilient supply chain practices and targeted channel engagement.

The combined pressures of tariff variability, regulatory heterogeneity, and evolving payer expectations necessitate proactive, multidisciplinary responses that align medical affairs, supply chain, commercial, and regulatory teams. By implementing the actionable recommendations outlined in this summary-focusing on evidence, formulation optimization, sourcing diversification, and tailored channel strategies-industry leaders can enhance their readiness to respond to market changes while preserving continuity of care for patients.

This conclusion underscores the imperative for coordinated execution across functional silos, continuous monitoring of clinical and policy developments, and investment in adaptive capabilities that ensure both clinical impact and operational sustainability for enzalutamide soft capsules.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Enzalutamide Soft Capsules Market, by Dosage Strength

  • 8.1. 120 Mg
  • 8.2. 40 Mg
  • 8.3. 80 Mg

9. Enzalutamide Soft Capsules Market, by Purchase Type

  • 9.1. New Prescription
  • 9.2. Refill

10. Enzalutamide Soft Capsules Market, by Indication

  • 10.1. Metastatic Castration-Resistant Prostate Cancer
  • 10.2. Metastatic Hormone-Sensitive Prostate Cancer
  • 10.3. Non-Metastatic Castration-Resistant Prostate Cancer

11. Enzalutamide Soft Capsules Market, by Distribution Channel

  • 11.1. Offline
  • 11.2. Online

12. Enzalutamide Soft Capsules Market, by End User

  • 12.1. Clinics
  • 12.2. Hospitals
    • 12.2.1. Private Hospital
    • 12.2.2. Public Hospital
  • 12.3. Specialty Centers

13. Enzalutamide Soft Capsules Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Enzalutamide Soft Capsules Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Enzalutamide Soft Capsules Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Enzalutamide Soft Capsules Market

17. China Enzalutamide Soft Capsules Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. Abbott Healthcare Private Limited
  • 18.6. Adley Formulations Private Limited
  • 18.7. Alizyme Healthcare Limited
  • 18.8. Aprazer Healthcare Private Limited
  • 18.9. Astellas Pharma Inc.
  • 18.10. BDR Pharmaceuticals International Private Limited
  • 18.11. Cipla Limited
  • 18.12. Dr. Reddy's Laboratories Limited
  • 18.13. Glenmark Pharmaceuticals Limited
  • 18.14. Halsted Pharma Private Limited
  • 18.15. Hetero Healthcare Limited
  • 18.16. Intas Pharmaceuticals Limited
  • 18.17. K. K. Pharma Solutions Private Limited
  • 18.18. Medisus Pharma Private Limited
  • 18.19. Pfizer Inc.
  • 18.20. RPG Life Sciences Limited
  • 18.21. Rutika Lifescience Private Limited
  • 18.22. Samarth Life Sciences Private Limited
  • 18.23. Sun Pharmaceutical Industries Limited
  • 18.24. Zydus Lifesciences Limited

LIST OF FIGURES

  • FIGURE 1. GLOBAL ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL ENZALUTAMIDE SOFT CAPSULES MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL ENZALUTAMIDE SOFT CAPSULES MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY DOSAGE STRENGTH, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY PURCHASE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY 120 MG, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY 120 MG, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY 120 MG, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY 40 MG, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY 40 MG, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY 40 MG, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY 80 MG, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY 80 MG, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY 80 MG, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY PURCHASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY NEW PRESCRIPTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY NEW PRESCRIPTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY NEW PRESCRIPTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY REFILL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY REFILL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY REFILL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY METASTATIC CASTRATION-RESISTANT PROSTATE CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY METASTATIC CASTRATION-RESISTANT PROSTATE CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY METASTATIC CASTRATION-RESISTANT PROSTATE CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY METASTATIC HORMONE-SENSITIVE PROSTATE CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY METASTATIC HORMONE-SENSITIVE PROSTATE CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY METASTATIC HORMONE-SENSITIVE PROSTATE CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY NON-METASTATIC CASTRATION-RESISTANT PROSTATE CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY NON-METASTATIC CASTRATION-RESISTANT PROSTATE CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY NON-METASTATIC CASTRATION-RESISTANT PROSTATE CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY OFFLINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY OFFLINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY OFFLINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY ONLINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY ONLINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY ONLINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY PRIVATE HOSPITAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY PRIVATE HOSPITAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY PRIVATE HOSPITAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY PUBLIC HOSPITAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY PUBLIC HOSPITAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY PUBLIC HOSPITAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY SPECIALTY CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY SPECIALTY CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY SPECIALTY CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. AMERICAS ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 55. AMERICAS ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 56. AMERICAS ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY PURCHASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 57. AMERICAS ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 58. AMERICAS ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 59. AMERICAS ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 60. AMERICAS ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 61. NORTH AMERICA ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. NORTH AMERICA ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 63. NORTH AMERICA ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY PURCHASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 64. NORTH AMERICA ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 65. NORTH AMERICA ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 66. NORTH AMERICA ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 67. NORTH AMERICA ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 68. LATIN AMERICA ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. LATIN AMERICA ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 70. LATIN AMERICA ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY PURCHASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 71. LATIN AMERICA ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 72. LATIN AMERICA ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 73. LATIN AMERICA ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 74. LATIN AMERICA ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 75. EUROPE, MIDDLE EAST & AFRICA ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 76. EUROPE, MIDDLE EAST & AFRICA ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 77. EUROPE, MIDDLE EAST & AFRICA ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY PURCHASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 78. EUROPE, MIDDLE EAST & AFRICA ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 79. EUROPE, MIDDLE EAST & AFRICA ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 80. EUROPE, MIDDLE EAST & AFRICA ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 81. EUROPE, MIDDLE EAST & AFRICA ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 82. EUROPE ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 83. EUROPE ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 84. EUROPE ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY PURCHASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 85. EUROPE ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 86. EUROPE ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 87. EUROPE ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 88. EUROPE ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 89. MIDDLE EAST ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. MIDDLE EAST ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 91. MIDDLE EAST ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY PURCHASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 92. MIDDLE EAST ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 93. MIDDLE EAST ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 94. MIDDLE EAST ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 95. MIDDLE EAST ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 96. AFRICA ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 97. AFRICA ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 98. AFRICA ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY PURCHASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 99. AFRICA ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 100. AFRICA ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 101. AFRICA ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 102. AFRICA ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 103. ASIA-PACIFIC ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 104. ASIA-PACIFIC ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 105. ASIA-PACIFIC ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY PURCHASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 106. ASIA-PACIFIC ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 107. ASIA-PACIFIC ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 108. ASIA-PACIFIC ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 109. ASIA-PACIFIC ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 111. ASEAN ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 112. ASEAN ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 113. ASEAN ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY PURCHASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 114. ASEAN ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 115. ASEAN ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 116. ASEAN ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 117. ASEAN ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 118. GCC ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 119. GCC ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 120. GCC ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY PURCHASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 121. GCC ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 122. GCC ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 123. GCC ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 124. GCC ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 125. EUROPEAN UNION ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 126. EUROPEAN UNION ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 127. EUROPEAN UNION ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY PURCHASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 128. EUROPEAN UNION ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 129. EUROPEAN UNION ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 130. EUROPEAN UNION ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 131. EUROPEAN UNION ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 132. BRICS ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 133. BRICS ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 134. BRICS ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY PURCHASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 135. BRICS ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 136. BRICS ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 137. BRICS ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 138. BRICS ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 139. G7 ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 140. G7 ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 141. G7 ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY PURCHASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 142. G7 ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 143. G7 ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 144. G7 ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 145. G7 ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 146. NATO ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 147. NATO ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 148. NATO ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY PURCHASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 149. NATO ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 150. NATO ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 151. NATO ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 152. NATO ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 153. GLOBAL ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 154. UNITED STATES ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 155. UNITED STATES ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 156. UNITED STATES ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY PURCHASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 157. UNITED STATES ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 158. UNITED STATES ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 159. UNITED STATES ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 160. UNITED STATES ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 161. CHINA ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 162. CHINA ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 163. CHINA ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY PURCHASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 164. CHINA ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 165. CHINA ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 166. CHINA ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 167. CHINA ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)